Radioimmunoimaging of Light Chain (AL) Amyloidosis
Radioimmunoimaging of Light Chain (AL) Amyloidosis
The purpose of the study is to determine the capability of a radiolabeled amyloid-reactive
 monoclonal antibody (mAb) to document the presence and distribution of amyloid deposits by
 PET/CT imaging in patients with AL amyloidosis.
To be eligible for this study, patients must have a confirmed diagnosis of AL amyloidosis
 without significant cardiac (New York Heart Association class IV) disease and not be on
 kidney dialysis. Additionally, after testing, their blood must not contain antibodies to
 mouse proteins. The study requires an intravenous infusion, given over 10 minutes, of the
 radiolabeled antibody, followed 48 hours later by a PET/CT scan. A repeat scan is done 5 days
 after infusion of the antibody. A 5-ml blood specimen needs to be furnished 4 and 8 weeks
 after the antibody infusion.
Inclusion Criteria:

 -  Patients with a confirmed diagnosis of AL amyloidosis.

 Exclusion Criteria:

 -  New York Heart Association class IV

 -  On renal dialysis

 -  Serum antibodies to mouse protein